DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT 45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer BUDAPEST, Hungary, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announces the first subject dosed in a two-part Phase I trial to evaluate the pharmacokinetics,...

Druggability Technologies Holdings, Ltd (DRGT) Announces Appointment of a New Chief Executive Officer and a New President of DRGT Research BUDAPEST, Hungary, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings, Ltd (DRGT), Ltd a clinical stage specialty pharmaceutical company, announced the appointment of Lynne Powell...